Our Commitment
At the Thoracic Oncology Group of Australasia (TOGA), we are committed to improving lung cancer treatment and survival. Through the design of world-class research and trials, we hope to give you access to advanced treatment.
Support us
Inspire lung cancer patients through funding research and trials.
Impactful education
An education program to better equip you to implement new findings into your care.
Join us
Be part of TOGA and share a mission to prevent, treat, and cure thoracic cancer.
Research ideas
Our expert review process assists in developing high-quality funding applications.
Key Statistics About Thoracic Cancer
Every
0
minutes
a person living with lung cancer in Australia loses their life.
0
+
healthcare
professionals
empowered to integrate research findings into standard of care.
0
patients
were tested during the ASPiRATION trial, resulting in life-saving interventions.
Featured News
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
